Sign in
SuspendedPhase 2

Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder

Key facts

Who runs it
University of Texas at Austin
Where
Austin, United StatesSee the site
Trial code
Status
Suspended
Phase
Phase 2
People taking part
150 people, planned
Started
15 Jan 2020
Ended
May 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CBD Isolate
  • CBD Broad Spectrum
  • Placebo oil
Record updated
22 November 2023
Why it stopped
Suspended (The UT IRB determined that CBD oil is being used as a drug as defined by the FDA. Therefore, an IND must be obtained for the use of CBD oil in this research study in accordance with FDA regulations, 21 CFR 312.)

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Meets for a current DSM-5 diagnosis of PTSD as their "primary" mental disorder
  • Age 18 or older
  • Fluent in English
  • Has access to the internet
  • Willingness to provide signed informed consent
  • Willingness to refrain from all non-study cannabis use during the study period

Who cannot take part

  • History of a suicide attempt within the past 6 months
  • History of psychosis within the past 6 months
  • History of current alcohol or substance use disorder within the past month
  • History of adverse reaction to CBD oil or other CBD products
  • Allergy to coconut oil
  • Any medical problems that would preclude participating in the study

Where in United States

  • Laboratory for the Study of Anxiety Disorders, University of Texas at AustinAustin, United States

About the trial

What the trial wants to find out

The overarching objective of the proposed project is to test the clinical efficacy of CBD in the treatment of post-traumatic stress disorder using a rigorous double-blind randomized clinical trial methodology. Participants (n=150) meeting full DSM-5 criteria for post-traumatic stress disorder (PTSD) will be randomized to one of 3 treatment arms: (a) CBD -Isolate; (b) CBD-Broad Spectrum; (c) Placebo oil.

Read full original descriptionShow less

We predict that patients receiving CBD isolate or CBD Broad Spectrum will show significantly greater improvements in PTSD symptoms and functional impairment at the posttreatment and one-month follow-up relative to patients receiving placebo oil. Additionally, we expect that patients receiving CBD Broad Spectrum will show significantly greater improvements relative to patients receiving CBD Isolate.

The 3 groups in the trial

  • CBD IsolateExisting treatment, for comparison

    300 mg/day of CBD isolate

  • CBD Broad SpectrumExisting treatment, for comparison

    300 mg/day of CBD Broad Spectrum Oil

  • Placebo oilPlacebo, for comparison

    Matched Placebo Oil

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Use of Cannabidiol (CBD) Oil in the Treatment of PTSD: A Placebo-Controlled Randomized Clinical Trial
Publications
Record updated
22 November 2023